The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. Year to date metric has recorded a loss of -15.02%.However, over the last six months, we can see a weaker performance of 20.86%. Over the last 30 days, the price of NAMS has fallen by 18.89%. And in the last five days, it has surged by 16.85%.
NewAmsterdam Pharma Company NV experienced a rather steady stock market performance.
52-week price history of NAMS Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. NewAmsterdam Pharma Company NV’s current trading price is -19.97% away from its 52-week high, while its distance from the 52-week low is 55.33%. The stock’s price range during this period has varied between$14.06 and $27.29. The NewAmsterdam Pharma Company NV’s shares, which operate in the Healthcare, saw a trading volume of around 1.44 million for the day, a figure considerably higher than their average daily volume of 0.92 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
NewAmsterdam Pharma Company NV (NAMS) has experienced a quarterly decline of -4.55% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 2.45B and boasts a workforce of 68 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
NAMS’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for NAMS stands at 0.00. Similarly, the long-term debt-to-equity ratio is also 0.00.
